The company said this could open the door for ... will face competition after its patent expires in 2028. A Merck logo is shown on a scientist's lab coat. The Food and Drug Administration, on ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the ...

OSR Holdings logo (PRNewsfoto/OSR Holdings) Dr. Höfer joins OSR Holdings from Merck Healthcare ... Her expertise will enhance the company's ability to identify and develop promising drug ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

In a decision filed March 28, Hon. Steven C. Seeger granted The Lansing Journal’s motion to dismiss the lawsuit filed by Lan-Oak Park District ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...

TD Cowen analyst Steve Scala maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of $100.00.

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on ...

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.